Celgene Corp. reported success in the phase III SUNBEAM trial evaluating the efficacy and safety of ozanimod – the oral selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator that was the crown jewel in its 2015 pick-up of Receptos Inc. – but offered few details. For the most part, analysts looked on the bright side, concluding that all is well.